Note: This is a Forecasted Prospect.

General Information Document Type: Grants Notice Opportunity Number: FOR-TR-27-002 Opportunity Title: Extracellular Vesicle Therapeutics for Regenerative Medicine (ExTReMe) Opportunity Category: Discretionary Opportunity Category Explanation: Funding Instrument Type: Cooperative Agreement Category of Funding Activity: Health Category Explanation: Expected Number of Awards: Assistance Listings: 93.350 -- National Center for Advancing Translational Sciences Cost Sharing or Matching Requirement: No Version: Forecast 1 Forecasted Date: Jun 27, 2025 Last Updated Date: Jun 27, 2025 Estimated Post Date: Oct 15, 2025 Estimated Application Due Date: Feb 17, 2026 Estimated Award Date: Dec 17, 2026 Estimated Project Start Date: Jan 18, 2027 Fiscal Year: 2027 Archive Date: Estimated Total Program Funding: Award Ceiling: Award Floor: Eligibility Eligible Applicants: County governments Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education Public and State controlled institutions of higher education Small businesses Independent school districts For profit organizations other than small businesses Native American tribal governments (Federally recognized) Public housing authorities/Indian housing authorities Native American tribal organizations (other than Federally recognized tribal governments) State governments Education Private institutions of higher education Additional Information on Eligibility: Additional Information Agency Name: National Institutes of Health Description:



The National Center for Advancing Translational Science (NCATS) seeks to advance its mission by advancing research on extracellular vesicles (EVs) and their use as therapeutics in the field of regenerative medicine. The main objective of this program, Extracellular Vesicle Therapeutics for Regenerative Medicine (ExTReMe), is to support the translation of EV-based therapeutics in regenerative medicine. EVs, like exosomes and microvesicles, are crucial mediators of intercellular communication, carrying diverse cargo like proteins, nucleic acids, and lipids.

In regenerative medicine, EVs play a significant role by influencing cellular behaviors during tissue repair and regeneration. Due to their natural function in intercellular communication, EVs represent a novel, cell-free, therapeutic tool. EVs can be further engineered to deliver therapeutic agents or modulate signaling pathways involved in repair/regeneration.

Areas of interest for ExTReMe could include, but are not limited to: direct EV therapy (stem cell-isolated EVs produced under GLP conditions, and stored as off-the-shelf therapies);

designer EVs (personalized to the individual patient’s needs). Grant authorities that allow the National Center for Advancing Translational Science (NCATS) to forecast this opportunity are as follows: 42 U.S. Code 287a - Cures Acceleration Network Link to Additional Information: Grantor Contact Information: Christine Happel, Ph.D.

National

Center for Advancing Translational Sciences (NCATS) (phone hidden) [email protected]

📌 Extracellular Vesicle Therapeutics for Regenerative Medicine (ExTReMe) (Bathinda)
🏢 The Warfighter Research Foundation
📍 Bathinda